Biomarin Withdraws Voxzogo Reimbursement Applic...

By HEOR Staff Writer

March 16, 2026

Voxzogo reimbursement Netherlands hangs in limbo after Biomarin's decision on March 12, 2026, to withdraw its application, leaving children with achondroplasia without access despite parental pleas.
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
Revised MenACWY Vaccination Strategy for Adolescents in Germany
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Transformative PBM Reform Legislation Signed into Law
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision